Acadia Q1 net loss narrows to $43M; DAYBUE approved and launched for Rett syndrome

ACADIA PHARMACEUTICALS INC

2023-Q1 EPS reported -$0.27 revenue$118,462,000

NUPLAZID net sales $118.5M, up 3% YoY; demand grew ~2%.
Net loss $43.0M ($0.27/share) vs $113.1M ($0.70/share) in Q1 2022.
DAYBUE (trofinetide) FDA-approved March 10; launched April 17 for Rett syndrome.
Phase 3 pimavanserin trial for negative schizophrenia symptoms nearing enrollment; results expected early 2024.
2023 guidance reaffirmed: NUPLAZID sales $520-$550M, R&D $235-$255M, SG&A $360-$380M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ACADIA PHARMACEUTICALS INC reported three months ended March 31, 2023 results: revenue $118.5 million, net income $43.0 million, or $0.27 per common share, EPS $0.27 per common share. Guidance reaffirmed.

Period: three months ended March 31, 2023
Revenue: $118.5 million
Net income: $43.0 million, or $0.27 per common share
EPS: $0.27 per common share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

language. --- EX-99 (EX-99.1) --- EX-99 Exhibit 99.1 Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID ® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUETM (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older on March 10, 2023 -

View on SEC.gov

Browse all earnings releases →

ACADIA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0000950170-23-018800

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.